1559 related articles for article (PubMed ID: 15313956)
1. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial.
Fox KA; Mehta SR; Peters R; Zhao F; Lakkis N; Gersh BJ; Yusuf S;
Circulation; 2004 Sep; 110(10):1202-8. PubMed ID: 15313956
[TBL] [Abstract][Full Text] [Related]
2. Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study.
Lewis BS; Mehta SR; Fox KA; Halon DA; Zhao F; Peters RJ; Keltai M; Budaj A; Yusuf S;
Am Heart J; 2005 Dec; 150(6):1177-84. PubMed ID: 16338255
[TBL] [Abstract][Full Text] [Related]
3. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study.
Peters RJ; Mehta SR; Fox KA; Zhao F; Lewis BS; Kopecky SL; Diaz R; Commerford PJ; Valentin V; Yusuf S;
Circulation; 2003 Oct; 108(14):1682-7. PubMed ID: 14504182
[TBL] [Abstract][Full Text] [Related]
4. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease.
Mehta SR; Yusuf S;
Eur Heart J; 2000 Dec; 21(24):2033-41. PubMed ID: 11102254
[TBL] [Abstract][Full Text] [Related]
5. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis.
Antman EM; Wiviott SD; Murphy SA; Voitk J; Hasin Y; Widimsky P; Chandna H; Macias W; McCabe CH; Braunwald E
J Am Coll Cardiol; 2008 May; 51(21):2028-33. PubMed ID: 18498956
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38).
Wiviott SD; Antman EM; Gibson CM; Montalescot G; Riesmeyer J; Weerakkody G; Winters KJ; Warmke JW; McCabe CH; Braunwald E;
Am Heart J; 2006 Oct; 152(4):627-35. PubMed ID: 16996826
[TBL] [Abstract][Full Text] [Related]
7. Renal function and outcomes in acute coronary syndrome: impact of clopidogrel.
Keltai M; Tonelli M; Mann JF; Sitkei E; Lewis BS; Hawken S; Mehta SR; Yusuf S;
Eur J Cardiovasc Prev Rehabil; 2007 Apr; 14(2):312-8. PubMed ID: 17446813
[TBL] [Abstract][Full Text] [Related]
8. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
Motovska Z; Kala P
Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
[TBL] [Abstract][Full Text] [Related]
9. Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation.
Mahoney EM; Mehta S; Yuan Y; Jackson J; Chen R; Gabriel S; Lamy A; Culler S; Caro J; Yusuf S; Weintraub WS;
Am Heart J; 2006 Jan; 151(1):219-27. PubMed ID: 16368322
[TBL] [Abstract][Full Text] [Related]
10. Clopidogrel in addition to aspirin reduces in-hospital major cardiac and cerebrovascular events in unselected patients with acute ST segment elevation myocardial.
Zeymer U; Gitt A; Jünger C; Bauer T; Heer T; Koeth O; Mark B; Zahn R; Senges J; Gottwik M
Thromb Haemost; 2008 Jan; 99(1):155-60. PubMed ID: 18217148
[TBL] [Abstract][Full Text] [Related]
11. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.
; Alexander JH; Becker RC; Bhatt DL; Cools F; Crea F; Dellborg M; Fox KA; Goodman SG; Harrington RA; Huber K; Husted S; Lewis BS; Lopez-Sendon J; Mohan P; Montalescot G; Ruda M; Ruzyllo W; Verheugt F; Wallentin L
Circulation; 2009 Jun; 119(22):2877-85. PubMed ID: 19470889
[TBL] [Abstract][Full Text] [Related]
12. Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy.
Pride YB; Wiviott SD; Buros JL; Zorkun C; Tariq MU; Antman EM; Braunwald E; Gibson CM;
Am Heart J; 2009 Sep; 158(3):e21-6. PubMed ID: 19699846
[TBL] [Abstract][Full Text] [Related]
13. Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.
Reaume KT; Regal RE; Dorsch MP
Ann Pharmacother; 2008 Apr; 42(4):550-7. PubMed ID: 18319394
[TBL] [Abstract][Full Text] [Related]
14. Patients with non-ST-elevation acute coronary syndromes undergoing coronary artery bypass grafting in the modern era of antithrombotic therapy.
Chew DP; Huang Z; Pieper KS; White H; Mahaffey KW; Ferguson JJ; Califf RM; Aylward PG
Am Heart J; 2008 Feb; 155(2):239-44. PubMed ID: 18215592
[TBL] [Abstract][Full Text] [Related]
15. The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden.
Lindgren P; Stenestrand U; Malmberg K; Jönsson B
Clin Ther; 2005 Jan; 27(1):100-10. PubMed ID: 15763611
[TBL] [Abstract][Full Text] [Related]
16. Clopidogrel: who, when, and how?
Cannon CP
Rev Cardiovasc Med; 2007; 8 Suppl 3():S27-34. PubMed ID: 17917618
[TBL] [Abstract][Full Text] [Related]
17. Acute clopidogrel use and outcomes in patients with non-ST-segment elevation acute coronary syndromes undergoing coronary artery bypass surgery.
Mehta RH; Roe MT; Mulgund J; Ohman EM; Cannon CP; Gibler WB; Pollack CV; Smith SC; Ferguson TB; Peterson ED
J Am Coll Cardiol; 2006 Jul; 48(2):281-6. PubMed ID: 16843176
[TBL] [Abstract][Full Text] [Related]
18. Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
Prescrire Int; 2009 Oct; 18(103):193-5. PubMed ID: 19877380
[TBL] [Abstract][Full Text] [Related]
19. Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
Aronow HD; Steinhubl SR; Brennan DM; Berger PB; Topol EJ;
Am Heart J; 2009 Feb; 157(2):369-74. PubMed ID: 19185647
[TBL] [Abstract][Full Text] [Related]
20. Balancing benefit against risk in the choice of therapy for coronary artery disease. Lesson from prospective, randomized, clinical trials of percutaneous coronary intervention and coronary artery bypass graft surgery.
Morrison DA; Sacks J
Minerva Cardioangiol; 2003 Oct; 51(5):585-97. PubMed ID: 14551526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
